Robeaute, founded in 2017, is developing a new class of therapeutic microrobots designed to diagnose, treat, and monitor the brain with a level of flexibility and precision not previously achievable. The company's work sits at the intersection of robotics, physics, material science, chemistry, biology, and medicine - an interdisciplinary approach reflected in a patent portfolio of over 50 filings.
The company's core product is a modular medical device built around a universal robotic core. Interchangeable micro-extensions allow the system to adapt to a range of neurosurgical applications, including tissue sampling, targeted therapy delivery, electrode implantation, and real-time data collection from deep within the brain.
Robeaute operates in the neurosurgery, medical devices, and biomedical engineering sectors. The company has raised $28 million (€27M) in Series A funding to advance its platform.
